SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Scien - Quaterly Results

02 Aug 2023 Evaluate
The Revenue for the quarter ended  June 2023 of Rs. 4753.22 millions grew by 12.32 % from Rs. 4231.90 millions.The Total Profit for the quarter ended June 2023 of Rs. 80.02 millions grew from Rs.-662.54 millions Operating profit Margin for the quarter ended June 2023 improved to 672.11% as compared to -535.67% of corresponding quarter ended June 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 4753.22 4231.90 12.32 4753.22 4231.90 12.32 18544.96 19790.03 -6.29
Other Income 116.47 74.65 56.02 116.47 74.65 56.02 840.66 1234.85 -31.92
PBIDT 672.11 -535.67 -225.47 672.11 -535.67 -225.47 1825.43 2001.15 -8.78
Interest 366.25 260.17 40.77 366.25 260.17 40.77 1386.82 742.41 86.80
PBDT 305.86 -795.84 -138.43 305.86 -795.84 -138.43 288.61 1258.74 -77.07
Depreciation 214.57 242.96 -11.69 214.57 242.96 -11.69 936.21 1043.66 -10.30
PBT 91.29 -1038.80 -108.79 91.29 -1038.80 -108.79 -647.60 215.08 -401.10
TAX 11.27 -376.26 -103.00 11.27 -376.26 -103.00 -694.42 -1586.80 -56.24
Deferred Tax 14.55 -376.26 -103.87 14.55 -376.26 -103.87 -195.99 -2.09 9277.51
PAT 80.02 -662.54 -112.08 80.02 -662.54 -112.08 46.82 1801.88 -97.40
Equity 903.03 898.04 0.56 903.03 898.04 0.56 903.03 897.90 0.57
PBIDTM(%) 14.14 -12.66 -211.71 14.14 -12.66 -211.71 9.84 10.11 -2.66

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×